<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of CureVac fell 42% in premarket trading on Thurdsay, a day after the German biotech said its COVID-19 vaccine was 47% effective in preventing the disease. CureVac’s study, conducted in 10 countries and involving 40,000 people, showed the vaccine’s struggle against a “fast changing environment” of at least 29 COVID-19 variants, with the original coronavirus strain “almost completely absent.
...read full article on Market Watch
